<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678535</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200048-052</org_study_id>
    <secondary_id>2007-004219-75</secondary_id>
    <nct_id>NCT00678535</nct_id>
  </id_info>
  <brief_title>Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer</brief_title>
  <acronym>EXPAND</acronym>
  <official_title>Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line
      treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a
      clinically relevant benefit for subjects with advanced gastric adenocarcinoma including
      gastroesophageal junction (GEJ) adenocarcinoma, in terms of progression free survival (PFS).

      Secondary objectives are to assess cetuximab plus XP versus XP alone with respect to overall
      survival, overall tumor response, quality of life (QoL) and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
    <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause within 60 days of the last tumor assessment or randomization. Participants without event are censored on the date of last tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)</time_frame>
    <description>The OS time is defined as the time from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Every 6 weeks until progression, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)</time_frame>
    <description>The BOR rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the best overall response, based on radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) from the IRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
    <description>Mean global health status and social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire</measure>
    <time_frame>Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
    <description>EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items are combined to obtain a single index score that is health utility index (HUI) score reflecting subject's preferences for different health states. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Time from first dose up to Day 30 after last dose of study treatment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">904</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab plus Capecitabine plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine plus Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cetuximab plus Capecitabine plus Cisplatin</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cetuximab plus Capecitabine plus Cisplatin</arm_group_label>
    <arm_group_label>Capecitabine plus Cisplatin</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cetuximab plus Capecitabine plus Cisplatin</arm_group_label>
    <arm_group_label>Capecitabine plus Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent before any study-related activities are carried out

          -  Age greater than or equal to (&gt;=) 18 years

          -  Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
             (Adenocarcinoma of the gastroesophageal junction [AEG] Types I-III according to
             Siewert classification)

          -  Archived tumor material sample for at least subsequent standardized Epidermal Growth
             Factor Receptor (EGFR) expression assessment

          -  Unresectable advanced (M0) or unresectable metastatic (M1) disease

          -  At least one radiographically documented measurable lesion in a previously
             non-irradiated area according to response evaluation criteria in solid tumors
             (RECIST). The primary tumor site is to be considered as a non-measurable lesion only

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Estimated life expectancy greater than (&gt;) 12 weeks

          -  Medically accepted contraception (if the risk of conception exists)

          -  Glomerular filtration rate (GFR) &gt;= 60 milliliter per minute (mL/min) The GFR is based
             on the Cockcroft-Gault formula for creatinine clearance

          -  Aspartate-aminotransferase (ASAT) less than or equal to (=&lt;) 2.5 * upper limit of
             normal (ULN) and alanine-aminotransferase (ALAT) =&lt; 2.5 *ULN

          -  Bilirubin =&lt; 3 * ULN

          -  Absolute neutrophil count (ANC) &gt;= 1.5 * 10^9 per liter

          -  Platelets &gt;= 100 * 10^9 per liter

          -  Hemoglobin &gt;=10 gram per deciliter (g/dL) (without transfusions)

          -  Sodium and potassium within normal limits or =&lt; 10 percent above or below
             (supplementation permitted)

        Exclusion Criteria:

          -  Prior chemotherapy, however, previous (neo-)adjuvant (radio-) chemotherapy allowed if
             finished &gt; 1 year prior to start of study treatment and no more than 300 mg/m^2
             cisplatin has been administered

          -  Prior treatment with an antibody or molecule targeting EGFR and/or Vascular
             Endothelial Growth Factor Receptor (VEGFR) related signaling pathways

          -  Brain metastasis and/or leptomeningeal disease (known or suspected)

          -  Radiotherapy (except localized radiotherapy for pain relief), major surgery or any
             investigational drug within 30 days before the start of study treatment

          -  Concurrent chronic systemic immune or hormone therapy not indicated in this study
             protocol (except for physiologic replacement)

          -  Clinically relevant coronary artery disease (New York Heart Association [NYHA]
             functional angina classification III/IV), congestive heart failure (NYHA III/IV),
             clinically relevant cardiomyopathy, history of myocardial infarction in the 12 months
             before study Screening, or high risk of uncontrolled arrhythmia

          -  Active Hepatitis B or C

          -  Chronic diarrhea or short bowel syndrome

          -  Presence of any contra-indication to treatment with cetuximab, capecitabine and
             cisplatin including:

               -  Known hypersensitivity to capecitabine, fluorouracil, cisplatin, cetuximab or to
                  any of the excipients of these drugs

               -  Known dihydropyrimidine dehydrogenase (DPD) deficiency

               -  Hereditary problems of galactose intolerance, Lapp lactase deficiency or
                  glucose-galactose malabsorption

               -  Current treatment with sorivudine or chemically related analogues, such as
                  brivudine

               -  Symptomatic peripheral neuropathy National Cancer Institute - Common Terminology
                  Criteria for Adverse Events (NCI-CTCAE) Grade &gt;= 2 and/or ototoxicity NCI CTCAE
                  Grade &gt;= 2, except if due to trauma or mechanical impairment due to tumor mass

          -  Pregnancy or lactation period

          -  Concurrent treatment with a non-permitted drug

          -  Treatment in another clinical study within 30 days prior to study screening

          -  Previous malignancy other than gastric cancer within 5 years prior to study screening,
             except for basal cell cancer of the skin or pre-invasive cancer of the cervix

          -  Medical or psychological conditions that would not permit the subject to complete the
             study or sign informed consent

          -  Legal incapacity or limited legal capacity

          -  Significant disease which, in the Investigator's opinion, would exclude the subject
             from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Lordick, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Leipzig, University Cancer Center Leipzig (UCCL), Leipzig Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Coburg VIC</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Frankston, VIC</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Steyr</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zams</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Verviers</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Jaú</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Santo André</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Sâo Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Reñaca</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Valparaiso</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Prague 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Paris 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Weilheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Petach Tiqva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Rozzano (Milano)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Inchon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Sana Maria da Feira</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Baia-Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>El Palmar-Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kaohsiung County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Democratic People's Republic of</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>March 30, 2013</results_first_submitted>
  <results_first_submitted_qc>March 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>1st line treatment for Gastric Cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Progression-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First/last participant (informed consent): June 2008/December 2010. Clinical data cut-off: 31 March 2012 Study completion 17 February 2013.</recruitment_details>
      <pre_assignment_details>Enrolled: 1,191 screened for eligibility; 287 excluded (mainly non-fulfillment of inclusion or exclusion criteria). 904 participants randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
          <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="P2">
          <title>Capecitabine Plus Cisplatin</title>
          <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="455">ITT population</participants>
                <participants group_id="P2" count="449">ITT population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="362">subjects who died before or at 31 March 2012</participants>
                <participants group_id="P2" count="351">subjects who died before or at 31 March 2012</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
          <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="B2">
          <title>Capecitabine Plus Cisplatin</title>
          <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="455"/>
            <count group_id="B2" value="449"/>
            <count group_id="B3" value="904"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="11.16"/>
                    <measurement group_id="B2" value="58.5" spread="10.83"/>
                    <measurement group_id="B3" value="58.3" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments</title>
        <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause within 60 days of the last tumor assessment or randomization. Participants without event are censored on the date of last tumor assessment.</description>
        <time_frame>Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
        <population>Intent-to-treat (ITT) population included all participants who were randomized to trial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments</title>
          <description>The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause within 60 days of the last tumor assessment or randomization. Participants without event are censored on the date of last tumor assessment.</description>
          <population>Intent-to-treat (ITT) population included all participants who were randomized to trial treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="4.2" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5.1" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary efficacy analysis: To test equality of progression free survival time between treatment groups, applying the two-sided stratified log-rank test (randomization strata: disease stage, previous oesophagectomy/gastrectomy and prior(neo−) adjuvant(radio) chemotherapy, α=5%).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3158</p_value>
            <method>Stratified log rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.920</ci_lower_limit>
            <ci_upper_limit>1.292</ci_upper_limit>
            <estimate_desc>Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>The OS time is defined as the time from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
        <time_frame>Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)</time_frame>
        <population>ITT population included all participants who were randomized to trial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The OS time is defined as the time from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.</description>
          <population>ITT population included all participants who were randomized to trial treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.3" upper_limit="10.6"/>
                    <measurement group_id="O2" value="10.7" lower_limit="9.4" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To test equality of OS time between treatment groups, applying the two-sided stratified log-rank test (randomization strata: disease stage, previous oesophagectomy/gastrectomy and prior (neo−) adjuvant(radio) chemotherapy, α=5%)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9547</p_value>
            <method>Stratified log rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.004</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.866</ci_lower_limit>
            <ci_upper_limit>1.165</ci_upper_limit>
            <estimate_desc>Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments</title>
        <description>The BOR rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the best overall response, based on radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) from the IRC.</description>
        <time_frame>Every 6 weeks until progression, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date, (31 Mar 2012)</time_frame>
        <population>ITT population included all participants who were randomized to trial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments</title>
          <description>The BOR rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the best overall response, based on radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) from the IRC.</description>
          <population>ITT population included all participants who were randomized to trial treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="25.7" upper_limit="34.3"/>
                    <measurement group_id="O2" value="29.2" lower_limit="25.0" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The best overall response rate was compared with the Cochran-Mantel-Haenszel test (strata: disease stage, previous oesophagectomy/gastrectomy and prior(neo−) adjuvant(radio) chemotherapy, two-sided with α=5%).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7696</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0435</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7844</ci_lower_limit>
            <ci_upper_limit>1.3882</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</title>
        <description>Mean global health status and social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
        <time_frame>Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
        <population>Analysis population included participants who had at least one evaluable EORTC QLQ-C30 questionnaire and were also included in the ITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</title>
          <description>Mean global health status and social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
          <population>Analysis population included participants who had at least one evaluable EORTC QLQ-C30 questionnaire and were also included in the ITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global health status: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.49" spread="22.168"/>
                    <measurement group_id="O2" value="57.19" spread="22.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.00" spread="21.879"/>
                    <measurement group_id="O2" value="61.80" spread="22.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.17" spread="20.796"/>
                    <measurement group_id="O2" value="63.35" spread="22.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.45" spread="20.015"/>
                    <measurement group_id="O2" value="61.83" spread="21.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.46" spread="22.978"/>
                    <measurement group_id="O2" value="63.61" spread="19.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.65" spread="21.722"/>
                    <measurement group_id="O2" value="64.11" spread="19.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.06" spread="22.629"/>
                    <measurement group_id="O2" value="57.72" spread="21.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.29" spread="21.558"/>
                    <measurement group_id="O2" value="62.64" spread="22.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.39" spread="21.317"/>
                    <measurement group_id="O2" value="66.67" spread="19.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.63" spread="16.198"/>
                    <measurement group_id="O2" value="66.67" spread="14.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status: Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.50" spread="13.918"/>
                    <measurement group_id="O2" value="61.81" spread="17.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.36" spread="27.077"/>
                    <measurement group_id="O2" value="76.52" spread="26.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.94" spread="28.885"/>
                    <measurement group_id="O2" value="75.70" spread="27.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.48" spread="26.547"/>
                    <measurement group_id="O2" value="75.65" spread="27.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.22" spread="25.317"/>
                    <measurement group_id="O2" value="75.51" spread="25.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.20" spread="26.143"/>
                    <measurement group_id="O2" value="78.26" spread="27.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.51" spread="24.766"/>
                    <measurement group_id="O2" value="76.67" spread="24.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.28" spread="21.730"/>
                    <measurement group_id="O2" value="73.58" spread="22.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.57" spread="27.348"/>
                    <measurement group_id="O2" value="78.16" spread="22.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.36" spread="22.705"/>
                    <measurement group_id="O2" value="78.00" spread="23.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.71" spread="27.682"/>
                    <measurement group_id="O2" value="80.56" spread="27.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning status: Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.33" spread="23.632"/>
                    <measurement group_id="O2" value="68.06" spread="32.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire</title>
        <description>EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items are combined to obtain a single index score that is health utility index (HUI) score reflecting subject's preferences for different health states. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QoL.</description>
        <time_frame>Baseline, Week 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
        <population>Analysis population included participants who had at least one evaluable EuroQoL EQ-5D questionnaire and were also included in the ITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire</title>
          <description>EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 single items are combined to obtain a single index score that is health utility index (HUI) score reflecting subject's preferences for different health states. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QoL.</description>
          <population>Analysis population included participants who had at least one evaluable EuroQoL EQ-5D questionnaire and were also included in the ITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.743" spread="0.240"/>
                    <measurement group_id="O2" value="0.749" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.739" spread="0.276"/>
                    <measurement group_id="O2" value="0.769" spread="0.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.752" spread="0.239"/>
                    <measurement group_id="O2" value="0.775" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.742" spread="0.251"/>
                    <measurement group_id="O2" value="0.755" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.733" spread="0.300"/>
                    <measurement group_id="O2" value="0.761" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.737" spread="0.301"/>
                    <measurement group_id="O2" value="0.790" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.710" spread="0.311"/>
                    <measurement group_id="O2" value="0.711" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.722" spread="0.209"/>
                    <measurement group_id="O2" value="0.689" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.719" spread="0.227"/>
                    <measurement group_id="O2" value="0.770" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.733" spread="0.275"/>
                    <measurement group_id="O2" value="0.730" spread="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.760" spread="0.322"/>
                    <measurement group_id="O2" value="0.742" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Number of Participants With Adverse Events (AEs)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
        <time_frame>Time from first dose up to Day 30 after last dose of study treatment, reported between day of first participant randomized, that is, 30 Jun 2008 until cut-off date (31 Mar 2012)</time_frame>
        <population>The safety population included all participants who received at least one dose of any trial treatment that is, cetuximab, cisplatin, or capecitabine.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
            <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine Plus Cisplatin</title>
            <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Number of Participants With Adverse Events (AEs)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
          <population>The safety population included all participants who received at least one dose of any trial treatment that is, cetuximab, cisplatin, or capecitabine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="446"/>
                <count group_id="O2" value="436"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446"/>
                    <measurement group_id="O2" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from first dose up to 30 days after the last dose of study treatment.</time_frame>
      <desc>An AE is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab Plus Capecitabine Plus Cisplatin</title>
          <description>Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] followed by 250 mg/m^2 intravenous infusion), cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days ) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="E2">
          <title>Capecitabine Plus Cisplatin</title>
          <description>Cisplatin (3-week cycle, 80 mg/m^2 intravenous infusion on Day 1) and capecitabine (3-week cycle, 1000 mg/m^2 orally twice daily for 14 days) until documented disease progression, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auricular perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Stent malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Electrocardiogram low voltage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Tumour rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="441" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="429" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="436"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="446"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="436"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merck.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

